» Articles » PMID: 35145187

ILF2 Enhances the DNA Cytosine Deaminase Activity of Tumor Mutator APOBEC3B in Multiple Myeloma Cells

Abstract

DNA cytosine deaminase APOBEC3B (A3B) is an endogenous source of mutations in many human cancers, including multiple myeloma. A3B proteins form catalytically inactive high molecular mass (HMM) complexes in nuclei, however, the regulatory mechanisms of A3B deaminase activity in HMM complexes are still unclear. Here, we performed mass spectrometry analysis of A3B-interacting proteins from nuclear extracts of myeloma cell lines and identified 30 putative interacting proteins. These proteins are involved in RNA metabolism, including RNA binding, mRNA splicing, translation, and regulation of gene expression. Except for SAFB, these proteins interact with A3B in an RNA-dependent manner. Most of these interacting proteins are detected in A3B HMM complexes by density gradient sedimentation assays. We focused on two interacting proteins, ILF2 and SAFB. We found that overexpressed ILF2 enhanced the deaminase activity of A3B by 30%, while SAFB did not. Additionally, siRNA-mediated knockdown of ILF2 suppressed A3B deaminase activity by 30% in HEK293T cell lysates. Based on these findings, we conclude that ILF2 can interact with A3B and enhance its deaminase activity in HMM complexes.

Citing Articles

Is It Possible to Predict Tumor Progression Through Genomic Characterization of Monoclonal Gammopathy and Smoldering Multiple Myeloma?.

Testa U, Leone G, Pelosi E, Castelli G, De Stefano V Mediterr J Hematol Infect Dis. 2024; 16(1):e2024044.

PMID: 38882455 PMC: 11178066. DOI: 10.4084/MJHID.2024.044.


The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma.

Nieto C, Miller B, Alzofon N, Chimed T, Himes J, Joshi M J Natl Cancer Inst. 2023; 115(11):1392-1403.

PMID: 37389416 PMC: 10637037. DOI: 10.1093/jnci/djad126.


APOBEC3B drives PKR-mediated translation shutdown and protects stress granules in response to viral infection.

Manjunath L, Oh S, Ortega P, Bouin A, Bournique E, Sanchez A Nat Commun. 2023; 14(1):820.

PMID: 36781883 PMC: 9925369. DOI: 10.1038/s41467-023-36445-9.

References
1.
An G, Acharya C, Deng S, Yi S, Xu Y, Qin X . Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment. Exp Hematol. 2014; 43(3):168-176.e2. DOI: 10.1016/j.exphem.2014.11.004. View

2.
Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

3.
Roelofs P, Goh C, Chua B, Jarvis M, Stewart T, McCann J . Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B. Elife. 2020; 9. PMC: 7553775. DOI: 10.7554/eLife.61287. View

4.
Yamazaki H, Shirakawa K, Matsumoto T, Hirabayashi S, Murakawa Y, Kobayashi M . Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells. Sci Rep. 2019; 9(1):7122. PMC: 6509214. DOI: 10.1038/s41598-019-43575-y. View

5.
Treon S, Maimonis P, Bua D, Young G, Raje N, Mollick J . Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood. 2000; 96(9):3147-53. View